Why does belly fat creep up after 30 even if nothing has changed? A California-based gastroenterologist trained at AIIMS explains the science behind it and what can help reverse it
From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions
Mounjaro is part of a new generation of weight-loss and diabetes drugs that target metabolic hormones. Introduced in March, it was launched ahead of rival Novo Nordisk's Wegovy
Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16
The development comes in line with growing obesity numbers in India, with a recent Lancet study projecting over 440 million obese and overweight people by 2050
India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising obesity and growing doctor awareness
With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment
Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May
A new Aiims study reveals a worrying rise in obesity, hypertension and hidden metabolic risks among Delhi schoolchildren, especially those in private schools
India's per capita oil intake has jumped to 23.5 kg a year-nearly twice the ICMR's limit-raising health concerns over obesity, heart disease, and diabetes
With obesity on the rise, Eli Lilly's weight-loss injection triggers a rush of consultations as Indians seek safer, cheaper options to black-market drugs
